Novavax is trading at $8.73, up 10.15% on August 19, 2026, alongside a broad biotech rally following Moderna’s positive Phase 3 melanoma vaccine results with Merck.

  • Reuters reported the trial met recurrence-free and metastasis-free survival goals.
  • No clear Novavax-specific announcement, earnings update, regulatory decision, or analyst action was identified.